European patients' registry for urea cycle defects and organic acidaemias (E-IMD) and European network and registry for homocystinurias and methylation defects (E-HOD) and European post marketing registry for RAVICTI® (Glycerolphenylbutyrat), oral liquid, in cooperation with the European registry and network for intoxication type metabolic diseases – E-IMD (RRPE) - E-IMD/ EHOD/ RRPE

Trial Profile

European patients' registry for urea cycle defects and organic acidaemias (E-IMD) and European network and registry for homocystinurias and methylation defects (E-HOD) and European post marketing registry for RAVICTI® (Glycerolphenylbutyrat), oral liquid, in cooperation with the European registry and network for intoxication type metabolic diseases – E-IMD (RRPE) - E-IMD/ EHOD/ RRPE

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 15 Dec 2017

At a glance

  • Drugs Glycerol phenylbutyrate (Primary)
  • Indications Inborn urea cycle disorders
  • Focus Therapeutic Use
  • Acronyms E-IMD/ EHOD/ RRPE
  • Most Recent Events

    • 15 Dec 2017 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top